Q-omics provides the consensus-scored RPL21P39 profile across patient tissues and cancer cell-line models. RPL21P39 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL21P39 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, RPL21P39 RNA expression shows 11,690 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, BRCA, and DLBC as cancer lineages where RPL21P39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL21P39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL21P39 survival associations across molecular data types. RPL21P39 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL21P39 RNA expression–survival associations across cancer types. High RPL21P39 expression shows unfavorable associations in ACC, COAD and BRCA, but favorable associations in CESC, MESO and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL21P39 RNA expression.
This table summarizes RPL21P39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL21P39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL21P39 shows lower tumor expression in BRCA, KICH, UCEC, LUSC and KIRP and higher tumor expression in COAD. The BRCA box plot shows higher RPL21P39 RNA expression in normal versus tumor tissue (log2 FC = −0.219, t-test p < 0.001).
This table shows molecular features associated with RPL21P39 in patient tissues and cancer cell lines. In patient samples, RPL21P39 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
